Multiple sclerosis.
Conditions
Interventions
Intervention 1: Intervention group 1:
50,000IU vitamin D
every five days,
for 3 months
vitamin D pearl
Zahravi Pharmaceuticals. Intervention 2: Control group: placebo tablet,
including inert su
Treatment - Drugs
Placebo
Intervention group 1:
50,000IU vitamin D
every five days,
for 3 months
vitamin D pearl
Zahravi Pharmaceuticals
Control group: placebo tablet,
including inert substance
one every five days,
made by a Pharmacist
Sponsors
Vice chancellor for research, Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: a definite diagnosis of Relapsing-remitting Multiple Sclerosis (RRMS) according to Mc Donald criteria? age 18 to 55 years? EDSS (Expanded Disability Status Scale) score of less than 4? no relapse 30 days before inclusion? negative ß-HCG test for women in child bearing age. Exclusion criteria: pregnancy? lactation? any other disease than Multiple Sclerosis? receiving>4000IU/d vitamin D? past history of renal or hepatic disease? relapse during the study? received corticosteroids in the previous 30 days? Calcium (Ca)>11mg/dl? Aspartate Transaminase(AST) or Alanine Transaminase(ALT)>3 times normal values? alkaline phosphatase (ALP)>2.5 times normal values.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interleukin 10, 17. Timepoint: At baseline and after 3 months. Method of measurement: Blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: 3 months. Method of measurement: MSQOL54. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFereshteh Ashtari
Isfahan University of Medical Sciences
Outcome results
None listed